Advertisement

Topics

Regenacy Pharmaceuticals Appoints Dr. William W. Chin to Board of Directors and Scientific Advisory Board

08:00 EDT 17 Apr 2018 | Businesswire

This article has expired, however you can still download the PDF.
Preview:
Regenacy Pharmaceuticals, LLC, a clinical-stage biopharmaceutical company developing breakthrough treatments for diabetic and other peripheral neuropathies, announced today the appointment of William (Bill) W. Chin, M.D.,...

Other Sources for this Article

Company Contact:
Regenacy Pharmaceuticals, LLC
John Rocha
Chief Financial Officer
jrocha@regenacy.com
or
Media Contact:
MacDougall Biomedical Communications
Kari Watson or Kara Mazey, 781-235-3060
kwatson@macbiocom.com
kmazey@macbiocom.com

NEXT ARTICLE

More From BioPortfolio on "Regenacy Pharmaceuticals Appoints Dr. William W. Chin to Board of Directors and Scientific Advisory Board"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Biopharmaceuticals
Biopharmaceuticals are medical drugs produced using biotechnology. They include proteins (including antibodies), nucleic acids (DNA, RNA or antisense oligonucleotides) and living microorganisms like virus and bacteria where the virulance of viruses and b...

Diabetes
Diabetes is a lifelong condition that causes a person's blood sugar level to become too high. The two main types of diabetes are: type 1 diabetes type 2 diabetes In the UK, diabetes affects approximately 2.9 million people. There are a...

Biotechnology Business
Alliances Astrazeneca Bioethics Boehringer Clinical Research Organization Collaborations GSK Johnson & Johnson Lilly Merck Mergers and Acquisitions Nexium Novartis Pfizer Roche Sanofi ...